Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 3/20 | 0.49 |
| ▸ | PIM1 | P11309 | 14/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16531919 | 1.00 | FYN (0.49) | FYNPIM1MKNK1KCNH2NTRK1 | |
| SCHEMBL17911327 | 0.90 | FYN (0.51) | FYNPIM1MKNK1KCNH2IRAK4 | |
| SCHEMBL16531916 | 0.90 | FYN (0.51) | FYNPIM1MKNK1KCNH2IRAK4 | |
| SCHEMBL17911322 | 0.88 | TYK2 (0.50) | — | |
| SCHEMBL16531926 | 0.88 | TYK2 (0.50) | — | |
| SCHEMBL16531913 | 0.88 | FYN (0.49) | FYNPIM1MKNK1KCNH2IRAK4 | |
| SCHEMBL16515738 | 0.88 | FYN (0.49) | FYNPIM1MKNK1KCNH2IRAK4 | |
| SCHEMBL16531917 | 0.80 | TYK2 (0.49) | — | |
| SCHEMBL17911319 | 0.80 | TYK2 (0.49) | — | |
| SCHEMBL16531912 | 0.79 | FYN (0.49) | FYNPIM1KCNH2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160199372-A1 | IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA | BRISTOL MYERS SQUIBB CO (US) | 2016-07-14 | — | — | US | claimed |
| US-20160199372-A1 | IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA | BRISTOL MYERS SQUIBB CO (US) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199372-A1 | IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA | AAK1, DAPK1, DAPK2 | FYN 123/4885PIM1 1123/4885MKNK1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.